HEART FAILURE IN CHRONIC KIDNEY DISEASE

Dr. Andrew House
Professor of Medicine
Chief of Nephrology
Western University and
London Health Sciences Centre
London, Ontario, Canada
• In May 2017, in Athens, Controversies Conference on Heart Failure in CKD
• High-quality data are lacking
  – pathophysiology, epidemiology, diagnosis, prevention, and treatment of HF
  – specific to the population of patients with advanced non-dialysis CKD as well as dialysis and transplant patients
Some Key Conclusions

- Improve understanding of pathophysiology of HF in CKD
- Changes in creatinine as representing “kidney damage” versus transient dynamic functional change is a great challenge
  - Biomarkers, improved imaging, refined definitions
- Urgent need for cardiologists and nephrologists to carry out clinical trials esp. in stage 4,5 CKD
- Determine optimal timing, mode, frequency of renal replacement therapy in patients with HF
- Better define role of potassium-lowering medications
Objectives

• To review the medical management options for patients with both advancing CKD and HF
• At the end of this talk, the audience will have a greater understanding of the limitations of current knowledge, and areas for future study
• As there is currently no evidence for any treatment of HF with preserved ejection fraction (HFpEF), irrespective of CKD, this talk focuses on HF with reduced EF (HFrEF)
Case presentation

- 82 year old man, long-standing HTN, remote MI, HF with reduced EF of 38%
- ASA 81 mg, Bisoprolol 2.5 mg, Furosemide 40 mg, Candesartan 8 mg, Atorvastatin 40 mg
- ACEi gives intolerable cough
- Symptoms under good control
- BP 118/72, HR 64, mild edema and few crackles
- eGFR between 27 and 30 mL/min/1.73m2, potassium always < 5.0 mmol/L
What is the scope of this? Global Problem

Between 45-65% of HF patients will have or develop CKD

500 million

Chronic Kidney Disease

40 million

Heart Failure
Cardio-Renal Pathophysiology

Cardiac Dysfunction

- ↑ Sympathetic Nervous System Activity
- ↑ Renin-Angiotensin-Aldosterone System Activity
- ↑ Afterload
- ↓ Cardiac Output
- ↑ Central Venous Pressure
- Na / H₂O Retention
- Inflammation
- Oxidative Stress
- Endothelial Dysfunction

Renal Dysfunction

↓ Renal Blood Flow / ↓ GFR

House AA. Am J Kidney Dis 2018
The goal of CHF treatment is to improve symptoms, function, QOL and decrease hospitalizations and mortality.

Class I recommendations for ACEi and beta blockers first line (substitute ARB where appropriate).

MRA for those who remains symptomatic.

Diuretics used for symptoms or signs of volume overload and congestion.
• Select groups may also qualify for:
  – Angiotensin receptor neprilysin inhibitor (ARNI)
  – Cardiac resynchronization therapy (CRT)
  – Implantable cardioverter defibrillator (ICD)
  – Ivabradine
  – Digoxin
  – Hydralazine-isosorbide dinitrate (H-ISDN)
  – Mechanical support or transplant
Guidelines and CKD

- Unfortunately, most clinical trials of RAS blockade have systematically excluded patients with advanced CKD (i.e. <30 mL/min/1.73m²)
- Stage 3 CKD (eGFR 30-59) much better represented in pivotal trials
- Small numbers of stage 4 CKD patients did get entered in trials (e.g. SAVE trial of captopril included ~10% of patients with eGFR <45)
- Beta blocker trials have tended to include more advanced CKD patients
Evidence for ACEi/ARB in CKD

• Survival and Ventricular Enlargement (SAVE) study of captopril versus placebo post-MI
• >2,200 patients with HFrEF and serum creatinine ≤ 2.5 mg/dL (220 umol/L)
• ~1/3 had eGFR < 60 mL/min/1.73 m²
• ~1/10 had eGFR < 45 mL/min/1.73 m²
• CKD patients did worse, but superiority of captopril was maintained in patients irrespective of CKD

Tokmakova et al, Circulation 2004
Worsening kidney function with ACEi/ARB

- Increase in creatinine, or decrease in GFR, is an expected “side effect” of ACEi or ARB
- HF studies that examine kidney outcomes generally show early decline in GFR with stabilization over time
- This does not equate to renal damage *per se*, as it is generally reversible upon reduction or withdrawal
- Studies in patients with renal disease show acute increases up to 30% that stabilize are strongly associated with renal protection
β-blockers in HF and CKD

- Metoprolol CR/XL (MERIT-HF) ~ 4,000 patients
  - ~500 patients with eGFR < 45 mL/min/1.73m²
  - HR for total mortality was 0.41 in favor of metoprolol for the CKD subgroup (as good or better than other subgroups)
- Bisoprolol (CIBIS II) ~ 2,600 patients
  - Included serum creat up to 300 µmol/L (3.4 mg/dL)
  - HR for death 0.66 (0.54-0.81)
  - No decrease in the benefits of bisoprolol with worsening kidney function

Ghali JK et al. J Card Fail 2009
Castagno D et al. Eur J Heart Fail 2010
Role of aldosterone in CRS

MRA / Aldosterone Blockade

• Pivotal trials of MRA (RALES and EPHESUS) showed benefits on treatment of advanced HF
• Looked at changes in creatinine over time, but as with RAS blockade, difficult to tease out the effect of initial changes in GFR due to ECFV contraction
• No examination of important long-term renal outcomes (doubling of Creat, renal death), nor any renal injury biomarkers
• Significant CKD and/or hyperkalemia were exclusions
MRA and severe CKD
Korean HF Registry

• ~1000 pts hospitalized for HF with eGFR < 45 mL/min
• Use of spironolactone assoc. with decreased mortality in univariate, but not multivariate analysis

Case

• Do guidelines apply to the patient in our case?
• Pretty borderline with eGFR between 27 and 30 mL/min
• ARB with good BP control, stable renal function, normal potassium so reasonable to leave it
• Beta blockers have a bit more evidence at levels below 30 mL/min
• MRA might be a consideration but high risk for hyperkalemia
Valsartan combined with sacubitril (NI) recommended in the ESC guidelines as a replacement for ACE inhibitor (or ARB)
– symptomatic HFrEF with LVEF \(\leq\) 35%
– symptomatic despite maximum-tolerated evidence-based doses of ACE inhibitors (or ARBs), \(\beta\)-blockers, and MRAs
PARADIGM-HF Trial
Enalapril vs ARNI

- ~8,400 patients with HFrEF
- stopped early due to an overwhelming benefit in overall mortality, CV mortality, hospitalizations, and HF symptoms in favour of ARNI
- Fewer ARNI patients experienced worsening kidney function or serious hyperkalemia
- Important exclusions:
  - baseline eGFR < 30 mL/min/1.73 m²
  - During run-in eGFR falling to <30 mL/min/1.73 m² or >35% decrease in eGFR
  - During run-in K ≥ 5.5 mEq/L

Hyperkalemia

• With combinations of ACEi or ARBs, MRAs, ARNIs, diabetes, CKD all are risks for hyperkalemia
• New agents (patiromer and ZS-9) which bind potassium are showing promise in allowing use of these agents in this population
• Cost, availability, limited post-marketing surveillance, potential for drug interactions / binding are potential limitations
Case continues

- During a severe bout of pneumonia, patient develops AKI, hyperkalemia, worsening CHF symptoms
- ARB and furosemide stopped
- At discharge he has more edema, eGFR is well below 20 mL/min and potassium is 5.2
- We reintroduce furosemide, then carefully resume ARB. Creatinine rises over 50% and potassium up to 5.6. Now what?
What to do for the truly ACEi/ARB intolerant patient?

- Hydralazine-isosorbide dinitrate (H-ISDN)
  - Opinion-based (mine) versus evidence-based
  - Fixed dose combination H-ISDN was used in African-American Heart Failure Trial (A-HeFT) added to standard therapy
    - ~40% reduction in mortality and hospitalization
    - Included 17% of patients with CKD
  - Very old trials V-HeFT I and II showed H-ISDN to be better than placebo for mortality
    - Incomplete data on kidney function

Taylor AL et al. Circulation. 2007
**General considerations**

- RAS blockade is of primary importance; may need to be reduced or withheld with worsening renal function.
- Aldosterone antagonists should be considered and cautiously monitored.
- Beta-blockers are important adjuncts in congestive heart failure and/or ischemic heart disease.
- ARNIis for symptomatic patients despite maximal tolerated doses of above agents.
- Concomitant iron deficiency may worsen symptoms and outcomes.

**Caveats/opportunities**

- Most studies exclude patients with significant kidney disease; increase in Creat > 30% or K > 5.0 mmol/L cause for concern.
- Creat > 2.5 mg/dL (>220 µmol/L) or K > 5.0 mmol/L were exclusions in clinical trials.
- Some agents (atenolol, nadolol, sotalol) have altered PK; carvedilol, bisoprolol and metoprolol are evidence based.
- eGFR <30 or decrease > 35% or K > 5.0 mmol/L all exclusions in PARADIGM.
- Parenteral iron improves symptoms, HF hospitalizations and mortality as well as renal function.
### What other considerations in the CKD population?

<table>
<thead>
<tr>
<th>General considerations</th>
<th>Caveats/opportunities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multifaceted, with traditional and non-traditional risk factors; graded risk based on degree of CKD</td>
<td>Lifestyle modification (smoking, weight control, activity, and nutrition) of probable benefit</td>
</tr>
<tr>
<td>Anemia closely related to poor outcomes; current guidelines recommend ESA for Hgb &lt; 100 g/L and targeting 100–120 g/L</td>
<td>Studies show increased harm from higher targets; concerns have been raised about stroke risk, and risk in patients with cancer</td>
</tr>
<tr>
<td>Management of CKD-MBD; phosphate binders, vitamin D analogs, controlling PTH</td>
<td>Efficacy largely limited to putative surrogate endpoints; trials with hard CV endpoints discouraging</td>
</tr>
<tr>
<td>Lipid lowering with statins</td>
<td>Efficacy in dialysis-dependent patients is questioned; in lesser degrees of CKD risk reduction is clearly established</td>
</tr>
</tbody>
</table>
Case conclusion (?)

- Uptitrated H-ISDN to maximum tolerated dose of 200 mg / 120 mg daily in four divided doses
- Flexible diuretic regimen to maintain target weight
- Followed in multidisciplinary CKD clinic with information on dialysis and conservative care
- Intermittent parenteral iron
- His symptoms, functional status and renal function stabilize
- Just celebrated his 90th birthday!!
Summary

• Worldwide rates of CKD are steadily increasing
  – Steady improvement in prevention and treatment of infectious disease, cancers and CVD
  – Aging population
  – High rates of diabetes and HTN

• Increased prevalence of patients suffering both CKD and HF
  – Shared risk factors between CKD and heart disease
  – Important contributions of CKD to HF and vice versa

• Significant gaps in the literature with more advanced CKD